Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center

Martin H. Voss, MD, discusses the clinical significance of the phase 3 KEYNOTE-564 trial in clear cell renal cell carcinoma.

Incorporating Treatment Advances Into mRCC Management

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

August 24th 2021

Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.

$Emerging Therapies for Relapsed/Refractory mRCC$

Emerging Therapies for Relapsed/Refractory mRCC

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

August 24th 2021

Novel strategies being explored in various stages of clinical trials as potential therapies for relapsed/refractory metastatic renal cell carcinoma.

$Relapsed/Refractory mRCC: Sequencing Therapy$

Relapsed/Refractory mRCC: Sequencing Therapy

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

August 17th 2021

Considerations for how to approach a patient with metastatic renal cell carcinoma previously treated with ipilimumab and nivolumab, followed by nivolumab maintenance.

$Treatment Approaches for Relapsed/Refractory mRCC$

Treatment Approaches for Relapsed/Refractory mRCC

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

August 17th 2021

An overview of treatment options for previously treated metastatic renal cell carcinoma.

Adjuvant Therapy Approaches for Operable RCC

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

August 10th 2021

A summary of current therapies and ongoing investigations of adjuvant therapy for patients with operable renal cell carcinoma.

Therapies Under Investigation for Frontline mRCC

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

August 10th 2021

Novel therapies currently being investigated as frontline options for metastatic renal cell carcinoma.

Favorable-Risk mRCC: Treatment Approaches

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

August 3rd 2021

A panel discussion regarding individual preferences for treating favorable-risk metastatic renal cell carcinoma.

Favorable-Risk mRCC: When to Initiate Therapy

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

August 3rd 2021

Dr Amishi Y. Shah, of MD Anderson Cancer Center, describes the rationale for active surveillance vs treatment with a novel therapeutic in metastatic renal cell carcinoma.

Intermediate/Poor-Risk mRCC: Treatment Selection

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

July 27th 2021

Factors oncologists should consider prior to selecting a novel treatment approach for metastatic renal cell carcinoma.

Intermediate/Poor-Risk mRCC: I-O/I-O Vs I-O/TKI Therapy

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

July 27th 2021

Variables that impact one’s decision to treat metastatic renal cell carcinoma with an immunotherapy-based regimen that includes a targeted agent vs additional immunotherapy.

I-O/TKI Regimens for Metastatic RCC: Dosing Strategies

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

July 20th 2021

Recommendations for dosing targeted therapy-immunotherapy combinations used to treat patients with metastatic renal cell carcinoma.

The CLEAR Trial in Metastatic RCC

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

July 20th 2021

Characteristics that distinguish the CLEAR trial of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma from other pivotal trials of immunotherapy plus tyrosine kinase inhibitors.

Frontline Metastatic RCC: Nivolumab Plus Cabozantinib

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

July 13th 2021

Robert S. Alter, MD, provides key takeaways from the CheckMate 9ER study of nivolumab plus cabozantinib as frontline therapy for patients with metastatic renal cell carcinoma.

Frontline Metastatic RCC: Pembrolizumab Plus Axitinib

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

July 13th 2021

Thomas Powles, MD, MBBS, MRCP, describes the KEYNOTE-426 trial in frontline metastatic renal cell carcinoma and comments on the use of pembrolizumab plus axitinib for appropriate patients.

Frontline Metastatic RCC: Nivolumab Plus Ipilimumab

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

July 6th 2021

Amishi Y. Shah, MD, comments on the significance of updated survival data revealed by the CheckMate 214 study using the combination of ipilimumab plus nivolumab as frontline therapy for metastatic renal cell carcinoma.

Frontline Treatment Advances in Metastatic RCC

Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Robert Alter, MD, John Theurer Cancer Center;Thomas Powles, MD, MBBS, MRCP, Barts Cancer Centre;Amishi Y. Shah, MD, MD Anderson Cancer Center;Sandy Srinivas, MBBS, Stanford Cancer Center

July 6th 2021

Dr. Sandy Srinivas comments on treatment approaches for frontline metastatic renal cell carcinoma based on the emergence of novel combination regimens that introduce immunotherapy.